Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aligos Therapeutics
Biotech
Aligos sells China rights to HBV drug in $445M deal
Aligos has secured a $25 million upfront fee from hepatology biopharma Amoytop for the China rights to its phase 2-stage HBV treatment.
James Waldron
Apr 16, 2026 9:12am
BMS snags top neuro researcher from Eisai—Chutes & Ladders
Jan 23, 2026 8:30am
Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders
Aug 22, 2025 8:30am
Acadia brings BMS vet on board as CEO—Chutes & Ladders
Sep 27, 2024 8:30am
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am
